NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has announced positive clinical data for its lead candidate NEO100, a development that could significantly impact the treatment landscape for recurrent brain cancer. The company's second quarter 2026 results, covered by Stonegate Capital Partners, reveal that NEO100 met its primary endpoint in a Phase 2a trial, with a six-month progression-free survival (PFS) rate of 48.9% as measured by RANO 2.0 criteria using Kaplan-Meier estimation, compared to a pre-specified benchmark of 20% (p=0.0047). Additionally, median overall survival (OS) reached 26.09 months, and no major toxicities were reported.
The survival data is particularly noteworthy, as current salvage therapy for recurrent brain cancer typically offers only 6–9 months of survival, according to management. While confirmation in a randomized study remains the next hurdle, the readout positions NEO100 for a potential registrational program. The company intends to request a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss trial design, endpoints, and the approval pathway. This regulatory alignment is now the key near-term catalyst for the company, as it could streamline the path to market.
Beyond NEO100, NeOnc is also advancing NEO212, a second clinical program that has gained regulatory momentum. NEO212 has received Phase 2 Chemistry, Manufacturing, and Controls (CMC) clearance and FDA feedback indicating a potential accelerated approval pathway. This broadens the company's investment case beyond a single asset, with NEO100 also being explored in meningioma and pediatric brain tumors, while NEO212 offers a differentiated approach. This platform breadth increases long-term optionality, although funding remains a critical factor as development activities expand.
Financially, the company's research and development expenses increased to $2.6 million in the second quarter, up from $0.7 million year-over-year, reflecting the accelerated clinical development. While financial results are secondary to the clinical progress, the company will need to secure additional capital to support the upcoming registrational trials and expanded pipeline.
The positive NEO100 data could have significant implications for patients with recurrent brain cancer, a condition with limited treatment options. If confirmed in larger trials, NEO100 could offer a new, well-tolerated therapy that extends survival. For the industry, this development underscores the potential of targeted therapies in oncology and may influence future trial designs in brain cancer. Investors will be watching for the outcome of the FDA meeting and the initiation of a randomized study, which will be critical for regulatory approval and market adoption.
